medmix stock: fair value
MEDX.SWThe fair value of medmix under our model is $7.51, the price is 66% above.
The fair value is an estimate from our model, not a price target.
Daily figure as of 13 Nov 2026
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $5.78 and expensive above $10.73 (uncertainty medium, based on the price swings of the past year).
Calculated with a cost of equity of 6.5%. At 7.5% the fair value would be $6.45, at 5.5% it would be $9.01.
Where the number comes from
From the cash-flow model alone; the profit includes one-off items, so there is no industry value.
Ten-year cash-flow model from smoothed free cash flow and its past growth until it reaches 0.6%. Discounted at 6.5% (government bond yield 0.6% plus beta 1.4 times a risk premium of 4.2%); no analyst estimates were available.
Calculate with your own assumptionsThe calculation step by step
With these figures the cash flow model arrives at $7.51 per share: free cash flow for the next ten years, each year discounted to today at 6.5%, plus the terminal value for the years after. The table explains the calculation; it is not a recommendation.
Calculation as a table
| Year | Free cash flow | Source | Discount factor | Present value (discounted at 6.5%) |
|---|---|---|---|---|
| 2026 | $25.32M | extrapolated at −6.3% | 0.9389 | $23.77M |
| 2027 | $24.25M | extrapolated at −4.2% | 0.8815 | $21.38M |
| 2028 | $23.58M | extrapolated at −2.8% | 0.8276 | $19.52M |
| 2029 | $23.17M | extrapolated at −1.8% | 0.7770 | $18M |
| 2030 | $22.93M | extrapolated at −1.1% | 0.7295 | $16.73M |
| 2031 | $22.8M | extrapolated at −0.5% | 0.6849 | $15.62M |
| 2032 | $22.75M | extrapolated at −0.2% | 0.6430 | $14.63M |
| 2033 | $22.76M | extrapolated at 0.0% | 0.6037 | $13.74M |
| 2034 | $22.81M | extrapolated at 0.2% | 0.5668 | $12.93M |
| 2035 | $22.88M | extrapolated at 0.3% | 0.5321 | $12.18M |
| Step | Value |
|---|---|
| Sum of present values (ten years) | $168.48M |
| Terminal value: cash flow 2035 × (1 + 0.6%) / (6.5% − 0.6%) | $389.39M |
| Present value of terminal value (× 0.5321) | $207.21M |
| Equity value (sum plus present value of terminal value) | $375.69M |
| Shares (diluted) | 50.00M |
| Value per share (equity value divided by shares) | $7.51 |
| Fair value (from the cash flow model alone) | $7.51 |
The model uses free cash flow after interest, which belongs to shareholders, discounted at the cost of equity. Net debt is therefore not deducted again.
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CHF 0.8331)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 25 Sep 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.